Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 50, Issue 6, 2010, Pages 645-649

  Alisi, Anna ^a   Manco, Melania ^a   Devito, Rita ^a   Piemonte, Fiorella ^b   Nobili, Valerio ^a  

^a Children's Hospital   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Endotoxin; Inflammation; NAFLD; NASH; PAI 1

Indexed keywords

BIOLOGICAL MARKER; ENDOTOXIN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENDOTOXEMIA; ENDOTOXIN DETECTION; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHILD; ENDOTOXINS; FATTY LIVER; FEMALE; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGRESSION ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953161601     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181c7bdf1     Document Type: Article

References (32)

1. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16.
2. Barshop NJ, Sirlin CB, Schwimmer JB, et al. Epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease [review article]. Aliment Pharmacol Ther 2008;28:13-24.
3. Patton HM, Sirlin C, Behling C, et al. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006;43:413-27.
4. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a"growing" problem? J Hepatol 2007;46:1133-42.
5. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007;128:837-47.
6. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-9.
7. Mager DR, Roberts EA. Nonalcoholic fatty liver disease in children. Clin Liver Dis 2006;10:109-31.
8. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006;26:1021-8.
9. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008;75:721-8.
10. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008;48(Suppl 1): S104-12.
11. Manco M, Marcellini M, Giannone G, et al. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 2007;127:954-60.
12. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27:412-21.
13. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007;17:1374-80.
14. Luyendyk JP, Maddox JF, Green CD, et al. Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology 2004;40:1342-51.
15. Beier JI, Luyendyk JP, Guo L, et al. Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharide-induced liver injury caused by ethanol in mice. Hepatology 2009;49:1545-53.
16. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology 2008;48:670-8.
17. Targher G, Bertolini L, Scala L, et al. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care 2007;30: e31-2.
18. Siebler J, Galle PR, Weber MM. The gut-liver-axis: endotoxemia, inflammation, insulin resistance and NASH. JHepatol 2008;48:1032-4.
19. Nobili V, Marcellini M, Marchesini G, et al. Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care 2007;30:2638-40. (Pubitemid 47547810)
20. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics Books; 1988.
21. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25-9.
22. Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70.
23. Abdul-Ghani MA, Matsuda M, Balas B, et al. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 2007;30:89-94.
24. Manco M, Bedogni G, Marcellini M, et al. Waist circumference correlates with liver fibrosis in children with nonalcoholic steatohepatitis. Gut 2008;57:1283-7.
25. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
26. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997;94:2557-62.
27. Dickerson RN, Karwoski CB. Endotoxin-mediated hepatic lipid accumulation during parenteral nutrition in rats. J Am Coll Nutr 2002;21:351-6.
28. Kirsch R, Clarkson V, Verdonk RC, et al. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. J Gastroenterol Hepatol 2006;21(1 Pt 1):174-82.
29. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of nonalcoholic steatohepatitis. Gut 2001;48:206-11.
30. Hocking MP, Davis GL, Franzini DA, et al. Long-term consequences after jejunoileal bypass for morbid obesity. Dig Dis Sci 1998;43:2493-9.
31. Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007;292: G518-25.
32. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008;138:1452-5.